Tissue factor pathway inhibitor and anti‐FXa kinetic profiles of a new low‐molecular‐mass heparin, Bemiparin, at therapeutic subcutaneous doses
作者:
L. Falkon,
M. Gari,
M. Barbanoj,
J. Amiral,
J. Fontcuberta,
期刊:
Blood Coagulation and Fibrinolysis
(OVID Available online 1998)
卷期:
Volume 9,
issue 2
页码: 137-142
ISSN:0957-5235
年代: 1998
出版商: OVID
关键词: low-molecular-mass heparin;tissue factor pathway inhibitor;pharmacokinetics
数据来源: OVID
摘要:
Low-molecular-mass heparins (LMMHs) exert an anti-FXa effect through antithrombin III (ATIII) and tissue factor pathway inhibitor (TFPI) displaced from endothelium and lipoproteins. This global anti-FXa potency is specific for different compounds. Whether these effects have a similar kinetic and duration is a matter of interest. We compared the kinetic profile of the TFPI effect (total and free) to the anti-FXa amidolytic activity induced by therapeutic subcutaneous doses of a new LMMH, Bemiparin. The overall kinetics of the anti-FXa amidolytic activity and the TFPI effect were different, TFPI achieving a maximal effect earlier than the anti-FXa activity and completely disappearing before it. The anti-FXa amidolytic activity of Bemiparin followed a linear dose-response pattern. Neither total nor free TFPI was directly proportional to the dose. At therapeutic subcutaneous doses, Bemiparin exerted an anti-FXa effect through TFPI during the first 2 h, through both ATIII and TFPI during the following 8 h (range 2–10 h) and through ATIII during the last 8 h (range 10–18 h). Blood Coag Fibrinol 9:137–141 × 1998 Lippincott-Raven Publishers.
点击下载:
PDF
(389KB)
返 回